

Allyn T Londregan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1836272/publications.pdf>

Version: 2024-02-01

21
papers

807
citations

623734

14
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

1026
citing authors

#	ARTICLE	IF	CITATIONS
1	General and Mild Preparation of 2-Aminopyridines. <i>Organic Letters</i> , 2010, 12, 5254-5257.	4.6	126
2	Mild Addition of Nucleophiles to Pyridine- <i>N</i> -Oxides. <i>Organic Letters</i> , 2011, 13, 1840-1843.	4.6	110
3	Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. <i>PLoS Biology</i> , 2017, 15, e2001882.	5.6	104
4	Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 474-479.	2.8	51
5	A New and Useful Method for the Macrocyclization of Linear Peptides. <i>Organic Letters</i> , 2012, 14, 2890-2893.	4.6	47
6	Identification of Tetrahydropyrido[4,3- <i>d</i>]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 63-68.	2.8	45
7	Expedient Synthesis of \pm -(2-Azaheteroaryl) Acetates via the Addition of Silyl Ketene Acetals to Azine- <i>N</i> -oxides. <i>Organic Letters</i> , 2014, 16, 3336-3339.	4.6	44
8	Preparation of Heteroaryl Ethers from Azine- <i>N</i> -Oxides and Alcohols. <i>Organic Letters</i> , 2016, 18, 1362-1365.	4.6	44
9	Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5704-5718.	6.4	37
10	Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 16218-16222.	13.8	35
11	Discovery of an <i>in Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1128-1133.	2.8	33
12	Rapid and Selective <i>in situ</i> Reduction of Pyridine- <i>N</i> -oxides with Tetrahydroxydiboron. <i>Synlett</i> , 2013, 24, 2695-2700.	1.8	30
13	Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1407-1411.	2.2	22
14	Expedient Synthesis of \pm -Heteroaryl Piperidines Using a Pd-Catalyzed Suzuki Cross-Coupling-Reduction Sequence. <i>Organic Letters</i> , 2014, 16, 413-415.	4.6	21
15	An improved amide coupling procedure for the synthesis of <i>N</i> -(pyridin-2-yl)amides. <i>Tetrahedron Letters</i> , 2009, 50, 1986-1988.	1.4	14
16	Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7164-7172.	6.4	14
17	Sequential Xanthalation and <i>O</i> -Trifluoromethylation of Phenols: A Procedure for the Synthesis of Aryl Trifluoromethyl Ethers. <i>Journal of Organic Chemistry</i> , 2019, 84, 15767-15776.	3.2	12
18	Discovery of <i>N</i> -(piperidin-3-yl)- <i>N</i> -(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3685-3688.	2.2	11

#	ARTICLE	IF	CITATIONS
19	The enantioselective synthesis of (R)- and (S)-3-amino-3,4-dihydro-1H-[1,8]naphthyridin-2-one. <i>Tetrahedron: Asymmetry</i> , 2010, 21, 2072-2075.	1.8	4
20	Synthesis and Analysis of Macrocyclic Peptides with 310-Helical Structure. <i>Synlett</i> , 2015, 26, 1164-1168.	1.8	2
21	Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. <i>Angewandte Chemie</i> , 2017, 129, 16436-16440.	2.0	1